Skip to content
Menu

HC Wainwright & Co. Reiterates Buy on Faeth Therapeutics, Maintains $60 Price Target

Benzinga Newsdesk 4 days ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $60 price target.

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $60 price target.

Read at benzinga.com